Jeffrey Wolf

Jeffrey Wolf

Founder, Chairman and CEO

Jeffrey Wolf is founder and CEO of Heat Biologics. He also founded Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies based upon breakthrough research.

Throughout his career, Mr. Wolf has specialized in building new life-science companies from the ground up and has played an active role in supporting the growth of his companies. Mr. Wolf's start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and chairman), which was focused on the development of novel bio-compatible polymers and recently sold to Medtronic and EluSys Therapeutics (founder and CEO), focused on the development of novel antibodies against infectious diseases. Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in economics.

Jeff Hutchins, Ph.D.

Jeff Hutchins, Ph.D.

Chief Scientific and Operating Officer

As Chief Scientific and Operating Officer, Jeff Hutchins oversees the research and development efforts for Heat Biologics, as well as for the company's subsidiary, Pelican Therapeutics. He brings more than 24 years of research and clinical development experience from both pharmaceutical- and biotechnology-focused companies. Prior to joining Heat Biologics, Dr. Hutchins served as Vice President of Pre-clinical Research for Peregrine Pharmaceuticals, Inc., a biopharmaceutical company developing therapeutics to fight cancer and infectious diseases. Dr. Hutchins was responsible for building out the research program for Peregrine's lead product candidate, bavituximab, a chimeric monoclonal antibody designed to target phosphatidylserine.

Prior to joining Heat Biologics, Dr. Hutchins served as Vice President, Preclinical Development at Inhibitex Inc, which was acquired by Bristol-Myers Squibb. From 1991 to 2000, Dr. Hutchins held several senior scientist positions in Discovery Research at Burroughs Wellcome and Glaxo Wellcome, with a visiting professor appointment at Rush Medical College.

Dr. Hutchins earned his Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at the M.D. Anderson Cancer Center, followed by postdoctoral training in the University of Southern California's Department of Microbiology at the Norris Cancer Center. Dr. Hutchins' publications and patents span the fields of oncology, infectious disease, osteoarthritis and immunology. He received his B.S. in Biology from Oral Roberts University.

George Peoples, M.D., FACS

George Peoples, M.D., FACS

Chief Medical Advisor

U.S. Army, COL (ret) George E. Peoples, MD, FACS, serves as CMO for both Heat Biologics and its subsidiary, Pelican Therapeutics. Dr. Peoples is currently professor of surgery at Uniformed Services University of the Health Sciences, as well as adjunct professor of surgical oncology at MD Anderson Cancer Center (MDACC). He is also the founder and director of Cancer Insight, LLC, a clinical research and development organization dedicated to the discovering, development and testing for emerging biotechnologies specializing in cancer immunotherapy. Dr. Peoples recently retired from 30 years of active duty as a surgeon and as a research scientist in the military. He is the past chair of the cancer program at the San Antonio Military Medical Center, and the past deputy director of the United States Military Cancer Institute. Prior to that, he served as chief of surgical oncology at Walter Reed Amy Medical Center (WRAMC), as well as SAMMC. He is a graduate of the United States Military Academy, West Point and Johns Hopkins School of Medicine. Dr. Peoples completed his surgical training at Harvard's Brigham and Women's Hospital, and during that time, also completed a post-doctoral fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MDACC. Dr. Peoples has written extensively on the immune response to cancer, with over 300 peer-reviewed manuscripts, abstracts and book chapters.

Lori McDermott, RN, BSN, MS, PMP

Lori McDermott, RN, BSN, MS, PMP

Vice President, Clinical Development

As Vice President of clinical development, Lori McDermott oversees the strategic and operational aspects of clinical drug development for Heat Biologics, as well as for the company’s subsidiary, Pelican Therapeutics.

Ms. McDermott brings more than 18 years of clinical operations and program management experience, spanning across large and small pharmaceutical companies, as well as contract research organizations. Prior to joining Heat Biologics, Ms. McDermott held positions of increasing responsibility at Astra-Zeneca, ICON, Bausch & Lomb, PPD and Peregrine Pharmaceuticals. Ms. McDermott’s responsibilities have included the execution of clinical trial programs, from Phase 1 to 4, with a recent focus on immunotherapy development in non-small cell lung cancer. Prior to her work in clinical research, Ms. McDermott practiced as a registered nurse and is currently licensed in Pennsylvania and Florida.

Ms. McDermott received an M.S. in clinical research organization and management from Drexel University College of Medicine, and her B.S. in Nursing from Neumann College. She is also certified as a PMP by the Project Management Institute.

William L. Ostrander

William L. Ostrander

Vice President of Finance and Secretary

As Vice President of Finance and Secretary, William Ostrander is responsible for all the company’s financial functions including accounting, audit, treasury, and corporate finance.

Bill has over 22 years of experience in financial management at public and private companies. Before joining Heat Biologics, Bill served as Executive Director of Finance at Liquidia Technologies, a publicly-traded biopharmaceutical company. Prior to that, he served as Senior Director of Finance and Accounting at KBI Biopharma, a biopharmaceutical contract services company. He also served as Manager of Finance at LexisNexis Risk Solutions, a data analytics solutions company. Prior to that, he served as Controller of Seisint Inc., a private information products company that was acquired by LexisNexis. He also served as Senior Manager, Finance and held other accounting and finance positions for Boca Research, a data communications hardware manufacturer. Ostrander holds a B.S. in Finance from Central Michigan University

Gary Vinson

Gary Vinson

Vice President, Chemistry and Manufacturing Controls (CMC)

As Vice President of Chemistry and Manufacturing Controls, Gary Vinson is responsible for all manufacturing and analytical development for Heat Biologics, as well as for the company's subsidiary, Pelican Therapeutics. He has more than 20 years of experience in the pharmaceutical, CRO/CMO and biotechnology industries, in technical, development and quality roles. Prior to joining Heat, he held roles as Vice President, Pharmaceutical Development at a specialty pharmaceutical company, BioDelivery Sciences, and at Aldagen, a clinical-stage regenerative medicine company developing adult cell therapies. His responsibilities have included leading manufacturing, analytical development and quality organizations, and he has significant experience developing CDMO outsourcing relationships from pre-IND through to registration. Mr. Vinson founded and was Managing Partner of The Perdoceo Group, LLC, a consulting firm providing CMC support to biotechnology and pharmaceutical clients. He began his career with Glaxo, Inc. and worked at Magellan Laboratories, where he was a principal in establishing the pharmaceutics group to provide contract development and manufacturing of clinical trial materials. Mr. Vinson received his B.S. In Chemistry from North Carolina State University and holds CPGP (Certified GMP Professional) and RAC (Regulatory Affairs Certification) certifications.

Cheni Kwok, Ph.D., CLP

Cheni Kwok, Ph.D., CLP

Senior Business Development Advisor

Dr. Kwok is a senior biopharmaceutical executive with broad operational expertise who has executed over 150 transactions including M&A, strategic partnerships, licensing, divestitures, spin-offs and project financing. Since 2011, Dr. Kwok is the Managing Partner and Founder of Linear Dreams LLC, a management consultancy for the life sciences industry. The firm engages a broad range of business and corporate development activities for 49 biopharmaceuticals companies, contract research & non-profit organizations, research institutes and investors in USA, Europe, China, Taiwan and Singapore.

As Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., Dr. Kwok established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, she was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics, including the divestiture of the oncology pipeline (including Imbruvica® (ibrutinib)) to Pharmacyclics Inc. (now an AbbVie Company). Dr. Kwok held business development positions of increasing responsibility at Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., she held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK).

Dr. Kwok received a bachelor's degree with first class honors in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, a Ph.D. in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional (CLP) credential. At present, Dr. Kwok is serving as the Board of Directors of Chinese-American Biopharmaceutical Society (CABS) and serves on the Standards, Admissions & Recertification committee of Certified Licensing Professionals, Inc.

Matthew M. Seavey, Ph.D.

Matthew M. Seavey, Ph.D.

Senior Director of Research

As Senior Director of Research, Matthew Seavey, holds over a decade in preclinical drug development experience.  Originally trained as an immunologist and an expert in early drug development, Matt has been involved in the development of different drug modalities (biologics, small molecules, cellular therapeutics, vaccines) across multiple therapeutic areas including, GI, CNS, immuno-oncology, respiratory, inflammation and cardio-metabolics.  Matt has held former positions as Drug Discovery Team Leader at Cephalon, Global Pharmacology Project Leader at Teva Pharmaceuticals, and Oncology Program Director at United Therapeutics.  Matt is a co-inventor on several patents and has contributed to the intellectual property base of Advaxis and founding of Oncoceutics.  Most recently Matt was Director of Preclinical Pharmacology for CinRx Pharma and founding partner of BioPoint Consulting, LLC.  Matt holds a BS in Microbiology from the University of Vermont, an MSc and PhD in Immunology from the University of Rochester and an MBA from West Chester University.